Medulloblastoma Clinical Trials

16 recruiting

Medulloblastoma Trials at a Glance

32 actively recruiting trials for medulloblastoma are listed on ClinicalTrialsFinder across 6 cities in 14 countries. The largest study group is Phase 1 with 13 trials, with the heaviest enrollment activity in Washington D.C., St Louis, and Miami. Lead sponsors running medulloblastoma studies include St. Jude Children's Research Hospital, Nationwide Children's Hospital, and Children's National Research Institute.

Browse medulloblastoma trials by phase

Treatments under study

About Medulloblastoma Clinical Trials

Looking for clinical trials for Medulloblastoma? There are currently 16 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Medulloblastoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Medulloblastoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 32 trials

Recruiting
Phase 3

Effect of Metformin on Behaviour and the Brain in Children Treated for a Brain Tumour

Cognitive ImpairmentMedulloblastoma, Childhood
Donald Mabbott140 enrolled20 locationsNCT05230758
Recruiting
Early Phase 1

A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.

PineoblastomaMedulloblastoma RecurrentEpendymoma Recurrent+3 more
Children's National Research Institute18 enrolled1 locationNCT07017816
Recruiting
Phase 2

DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma

Medulloblastoma
Giselle Sholler118 enrolled24 locationsNCT04696029
Recruiting
Phase 1

RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB)

Recurrent Medulloblastoma
University of Florida24 enrolled1 locationNCT07492316
Recruiting

CSIMEMPHIS: Long-term Follow-up of Medulloblastoma Survivors That Received Craniospinal Irradiation

Medulloblastoma
St. Jude Children's Research Hospital184 enrolled1 locationNCT07085325
Recruiting
Not Applicable

Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma

MedulloblastomaEpendymomaEpendymoma of Brain+3 more
University of California, San Francisco74 enrolled8 locationsNCT05057702
Recruiting
Phase 1Phase 2

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

Solid Tumor CancerHigh Risk NeuroblastomaMedulloblastoma
Fundación de investigación HM25 enrolled1 locationNCT06607692
Recruiting

Relapsed and Progressive Sonic Hedgehog Medulloblastoma With U1 Mutation Registry Study

Medulloblastoma RecurrentMedulloblastoma, Childhood, RecurrentMedulloblastoma, SHH-activated and TP53 Mutant+1 more
Mohammad H. Abu Arja300 enrolled2 locationsNCT07242963
Recruiting
Phase 1Phase 2

Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors

MeningiomaRecurrent Diffuse Intrinsic Pontine GliomaHigh Grade Glioma+10 more
Nationwide Children's Hospital65 enrolled4 locationsNCT05278208
Recruiting
Phase 1

Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors

Germ Cell TumorChoroid Plexus CarcinomaCentral Nervous System Tumor+8 more
Seattle Children's Hospital90 enrolled1 locationNCT04185038
Recruiting
Phase 1

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

NeoplasmsNeoplasms by SiteBrain Diseases+30 more
M.D. Anderson Cancer Center24 enrolled3 locationsNCT03911388
Recruiting
Phase 2

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

High Grade GliomaDiffuse Intrinsic Pontine GliomaRecurrent Medulloblastoma
Nationwide Children's Hospital120 enrolled12 locationsNCT05096481
Recruiting
Phase 1Phase 2

PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications

GlioblastomaGliomaMedulloblastoma+1 more
National Cancer Institute (NCI)146 enrolled1 locationNCT06161519
Recruiting
Phase 1

Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)

PineoblastomaEmbryonal Tumor With Multilayered RosettesEpendymoma+3 more
Children's National Research Institute12 enrolled1 locationNCT06193759
Recruiting
Early Phase 1

Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation

CNS Embryonal TumorCNS, Medulloblastoma
C17 Council15 enrolled12 locationsNCT06942039
Recruiting
Phase 2

Digoxin Medulloblastoma Study

MedulloblastomaMedulloblastoma, Non-WNT/Non-SHH
H. Lee Moffitt Cancer Center and Research Institute23 enrolled15 locationsNCT06701812
Recruiting
Phase 3

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

Childhood Medulloblastoma
Children's Oncology Group225 enrolled103 locationsNCT05382338
Recruiting
Phase 2

Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors

Medulloblastoma RecurrentEpendymoma RecurrentATRT Recurrent+1 more
Medical University of Vienna232 enrolled22 locationsNCT01356290
Recruiting
Phase 2

Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

Medulloblastoma
St. Jude Children's Research Hospital130 enrolled10 locationsNCT05535166
Recruiting
Phase 1

GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults

Pediatric Brain TumorPineoblastomaMedulloblastoma+7 more
Stanford University18 enrolled1 locationNCT07087002